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Device Therapies Among Patients Receiving Primary Prevention
Implantable Cardioverter-Deﬁbrillators in the Cardiovascular
Research Network
Robert T. Greenlee, PhD, MPH; Alan S. Go, MD; Pamela N. Peterson, MD, MSPH; Andrea E. Cassidy-Bushrow, PhD; Charles Gaber, MPH;
Romel Garcia-Montilla, MD, PhD, MSc; Karen A. Glenn, BS; Nigel Gupta, MD; Jerry H. Gurwitz, MD; Stephen C. Hammill, MD; John J. Hayes,
MD; Alan Kadish, MD; David J. Magid, MD, MPH; David D. McManus, MD; Deborah Multerer; J. David Powers, MS; Liza M. Reiﬂer, MPH;
Kristi Reynolds, PhD, MPH; Claudio Schuger, MD; Param P. Sharma, MD; David H. Smith, PhD, RPh; Mary Suits, BSN; Sue Hee Sung, MPH;
Paul D. Varosy, MD; Humberto J. Vidaillet, MD; Frederick A. Masoudi, MD, MSPH
Background-—Primary prevention implantable cardioverter-deﬁbrillators (ICDs) reduce mortality in selected patients with left
ventricular systolic dysfunction by delivering therapies (antitachycardia pacing or shocks) to terminate potentially lethal
arrhythmias; inappropriate therapies also occur. We assessed device therapies among adults receiving primary prevention ICDs in
7 healthcare systems.
Methods and Results-—We linked medical record data, adjudicated device therapies, and the National Cardiovascular Data
Registry ICD Registry. Survival analysis evaluated therapy probability and predictors after ICD implant from 2006 to 2009, with
attention to Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups: left ventricular ejection
fraction, 31% to 35%; nonischemic cardiomyopathy <9 months’ duration; and New York Heart Association class IV heart failure
with cardiac resynchronization therapy deﬁbrillator. Among 2540 patients, 35% were <65 years old, 26% were women, and 59%
were white. During 27 (median) months, 738 (29%) received ≥1 therapy. Three-year therapy risk was 36% (appropriate, 24%;
inappropriate, 12%). Appropriate therapy was more common in men (adjusted hazard ratio [HR], 1.84; 95% conﬁdence interval [CI],
1.43–2.35). Inappropriate therapy was more common in patients with atrial ﬁbrillation (adjusted HR, 2.20; 95% CI, 1.68–2.87), but
less common among patients ≥65 years old versus younger (adjusted HR, 0.72; 95% CI, 0.54–0.95) and in recent implants (eg, in
2009 versus 2006; adjusted HR, 0.66; 95% CI, 0.46–0.95). In Centers for Medicare and Medicaid Services Coverage With Evidence
Development analysis, inappropriate therapy was less common with cardiac resynchronization therapy deﬁbrillator versus single
chamber (adjusted HR, 0.55; 95% CI, 0.36–0.84); therapy risk did not otherwise differ for Centers for Medicare and Medicaid
Services Coverage With Evidence Development subgroups.
Conclusions-—In this community cohort of primary prevention patients receiving ICD, therapy delivery varied across demographic
and clinical characteristics, but did not differ meaningfully for Centers for Medicare and Medicaid Services Coverage With Evidence
Development subgroups. ( J Am Heart Assoc. 2018;7:e008292. DOI: 10.1161/JAHA.117.008292.)
Key Words: arrhythmia • implantable cardioverter-deﬁbrillator • inappropriate shock •outcomes research •sudden cardiac death
I n clinical trials of selected patients with left ventricularsystolic dysfunction, implantable cardioverter-deﬁbrillators
(ICDs) reduce risk of death as a primary prevention strategy.1–3
These devices detect and terminate life-threatening ventricular
tachyarrhythmias with device-delivered therapies (antitachy-
cardia pacing and/or high-voltage shocks). However,
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inappropriate device therapies can also be delivered in
response to nonlethal tachyarrhythmias or as a result of device
malfunction. Inappropriate ICD therapies are associated with
subsequent morbidity and mortality, worsening health status,
and cost.4–6 A greater understanding of the incidence and
predictors of device therapies, both appropriate and inappro-
priate, after primary prevention ICD implantation is needed to
optimize clinical decision making and to inform health policy.7
In practice, the use of primary prevention ICDs has
expanded beyond the selected participants in clinical trials,
with almost 200 000 devices implanted annually in the United
States.8 Because patients receiving care in the community
differ from those enrolled in trials, outcomes of ICD therapy in
clinical practice may also vary.8–10 When expanding Medicare
coverage for ICDs in 2005, the Centers for Medicare and
Medicaid Services (CMS) issued a “Coverage With Evidence
Development” (CED) decision that established a national
registry of patients receiving primary prevention ICDs to
address knowledge gaps in patient selection and clinical
decision making.11 Three patient subgroups required further
study: those with left ventricular ejection fraction, 31% to
35%; those with nonischemic dilated cardiomyopathy (NIDCM)
of <9 months’ duration; and those with New York Heart
Association (NYHA) class IV heart failure symptoms with a
cardiac resynchronization therapy deﬁbrillator (CRT-D).12
Within the framework of the LS-ICD (Longitudinal Study of
Implantable Cardioverter Deﬁbrillators),13 we aimed to
describe the occurrence of appropriate and inappropriate
device-delivered therapies in contemporary practice and to
identify device therapy predictors, with particular attention to
CMS CED subgroups.
Methods
Setting and Study Population
The LS-ICD is a retrospective study of primary prevention
ICDs within 7 geographically distributed community-based
healthcare systems participating in the Cardiovascular
Research Network.13,14 We identiﬁed all adults receiving an
ICD for primary prevention between January 1, 2006, and
December 31, 2009, excluding patients if they had a left
ventricular ejection fraction >35%, if they had previously
received an ICD, or if follow-up data were not available. The
study was approved by institutional review boards at partic-
ipating sites, with waiver of informed consent because of the
observational nature of the study.
Data Sources
The LS-ICD links baseline patient and device characteristics
from the National Cardiovascular Data Registry ICD
Registry,8 additional baseline and longitudinal clinical data
(diagnoses, procedures, laboratory test results, and medica-
tions) from the electronic health records of participating
sites,14,15 a novel repository of device-delivered therapies
ascertained through manual record review by trained local
abstractors coupled with remote device monitoring data
sources when used, and centralized clinical adjudication.13
Although study materials have been made available in a
supplemental appendix to a previous publication,13 study
data for this analysis are not directly available to other
researchers for purposes of reproducing the results or
replicating the procedure.
Outcomes
Patients were observed for up to 3 years after ICD placement
for device interrogations and the occurrence of device
therapies, with those receiving ICDs in 2009 followed up for
up to 2 years. Of >28 000 device interrogations, 60% were
from ambulatory clinic visits, 33% were from remote moni-
toring sources, and 6% were from hospital sources. For those
patients with ≥10 therapy episodes (n=61), adjudication was
limited to the ﬁrst 10, and a maximum of 3 therapies were
collected from any 24-hour period to limit potential inﬂuence
of ventricular tachycardia (VT) “storm.”16 Device therapies
were reviewed by 2 members of a central clinical panel (H.V.,
Clinical Perspective
What Is New?
• In this large observational cohort study of community
practice patients receiving an implantable cardioverter-
deﬁbrillator for primary prevention of sudden cardiac death,
the occurrence of device therapies was generally lower than
reported in efﬁcacy trials (3-year cumulative probability of
ﬁrst device therapy was 36% for therapies of any type and
24% for shocks). We have found that the occurrence of both
appropriate and inappropriate device therapies was similar
for patient subgroups identiﬁed for further study by the
Centers for Medicare and Medicaid Services, when com-
pared with their counterparts, even after accounting for
differences in baseline device programming.
What Are the Clinical Implications?
• On the basis of a large and broadly representative
population of patients from several US health systems, this
study offers useful prognostic information to providers and
patients on the likelihood of appropriate and inappropriate
device therapies occurring after implantable cardioverter-
deﬁbrillator placement for primary prevention, across a
range of demographic, clinical, and device characteristics.
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P.S., J.H., and R.G.M.) to conﬁrm the episode, type of therapy,
and therapy appropriateness on the basis of device interro-
gation reports and intracardiac electrograms. Therapies were
classiﬁed as appropriate (in response to a potentially
malignant ventricular tachyarrhythmia) or inappropriate (at-
tributable to other causes, including supraventricular arrhyth-
mias, or problems with device sensing or function).13 Review
relied on local provider interpretation, as documented in
clinical notes in absence of device documentation (28% of
episodes). Therapy appropriateness was deemed uncertain
when sources were inadequate or unavailable (15% of
episodes). Device therapies were classiﬁed as antitachycardia
pacing alone or as a therapy resulting in shock (either
antitachycardia pacing followed by shock or shock alone).
Discrepancies between reviewers were resolved by consen-
sus, with additional review by expert electrophysiology
adjudicators (S.H., A.K., and P.V.) for unresolved discrepan-
cies and quality assurance.
Patient Characteristics
Patient characteristics included the following: age, sex, race/
ethnicity, year of implant, device type, left ventricular ejection
fraction, cause (ischemic/nonischemic) and duration of
cardiomyopathy, NYHA functional class, cardiovascular and
other comorbidities (previous coronary artery bypass graft,
previous percutaneous coronary intervention, lung disease,
diabetes mellitus, hypertension, atrial ﬁbrillation, QRS dura-
tion, left bundle branch block morphological features, and
nonsustained VT), select laboratory values (blood urea
nitrogen and serum creatinine), and medications prescribed
at discharge after ICD implant, including angiotensin-convert-
ing enzyme inhibitors, angiotensin II receptor blockers,
aspirin, b blockers, digoxin, and statins. Special attention
was given to patient subgroups designated for further
evaluation by CMS in their 2005 CED decision for primary
prevention ICDs. Baseline device settings, including arrhyth-
mia detection enhancements (on/off) and lowest pro-
grammed rate threshold for delivery of tachyarrhythmia
therapy (<180, 180–199, and >200 beats per minute
[bpm]), were available in 74% of patients.
Statistical Analysis
All analyses were conducted using SAS 9.3 (SAS Institute, Inc,
Cary, NC). We ﬁrst estimated crude incidence density rates of
total device-delivered therapies. Kaplan-Meier curves were
generated for time to ﬁrst device-delivered therapy, stratiﬁed
by therapy appropriateness, both overall and within the
predeﬁned CMS CED subgroups. For each subject, follow-up
time accrued from date of implant until the event of interest
or censoring at the earliest of the following: end of the
observation period, date of last device interrogation, date of
death, or date of device deactivation/explantation.
Cox regression assessed correlates of time to ﬁrst
appropriate therapy and time to ﬁrst inappropriate therapy.
All candidate variables associated with the outcome with a
univariate P<0.20 and the CMS subgroup variables were
included in ﬁnal models, along with study site as a random
effect to account for clustering. Proportional hazard assump-
tions were evaluated by modeling covariate-by-time interac-
tions, and potential collinearity among covariates was
evaluated using condition indexes and variance decomposi-
tion proportions.17 For the few variables with negligible
missing values (<0.4% of records), simple imputation used the
mode. For the 2 variables with greater missing proportions,
cardiomyopathy cause/duration (1.1%) and QRS duration and
morphological features (9.0%), missing values were assigned a
separate category.18
Sensitivity Analyses
We explored potential bias from outcome misclassiﬁcation
because of therapies with uncertain appropriateness, using
probabilistic bias analysis with record-level replacement.19 In
a second sensitivity analysis, we explored secular changes in
baseline device programming during the course of the study
and evaluated the potential inﬂuence of incorporating device
setting information on the observed outcomes of our primary
analysis.
Results
Baseline Characteristics
Among 2669 initial patients, we excluded 129 who had a
previous ICD placement, a left ventricular ejection fraction
>35%, or a lack of follow-up care in the implanting health
system, leaving a ﬁnal analysis set of 2540 study subjects
(Figure 1). The proportion of total study subjects ascertained
from each of the 7 study sites ranged from 5% to 30%. Of the
study group, 26% were women, 35% were <65 years old, and
59% were non-Hispanic white (Table 1). Histories of clinical
heart failure (96.3%) and hypertension (73.1%) were common.
With respect to subgroups identiﬁed in the CMS CED criteria,
358 patients (14.1%) had a left ventricular ejection fraction of
31% to 35%, 183 patients (7.2%) had NIDCM <9 months’
duration, and 31 patients (1.2%) had NYHA class IV heart
failure symptoms and CRT-D. Because of the small number in
this last group, NYHA class and device type were considered
separately. Most patients in the study cohort had NYHA class
II (47.2%) or class III (39.5%) symptoms, and there was
balanced representation of device type (single chamber,
35.6%; dual chamber, 31.9%; and CRT-D, 32.4%).
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Device Therapy Rates
During a median follow-up of 27 months, 29.1% of patients
experienced at least 1 episode that resulted in delivery of a
device therapy (20% had ≥1 appropriate therapy, and 11%
had ≥1 inappropriate therapy). On review of the 2455
therapy episodes received by these subjects, 55% were
classiﬁed as appropriate, 30% were classiﬁed as inappropri-
ate, and 15% were deemed unclassiﬁable on the basis of the
clinical information available (Figure 1). Approximately 43%
of treated episodes resulted in a shock. Of 738 patients
receiving device therapies, 38% had 1, 31% had 2 to 3, 23%
had 4 to 9, and 8% had ≥10 therapy episodes. Patient
characteristics and corresponding therapy incidence rates
are shown in Table 1.
The cumulative probability of a ﬁrst device therapy of any
type at 3 years was 36% (24% appropriate and 12% inappro-
priate; Figure 2). The 3-year cumulative probability of a ﬁrst
therapy resulting in shock was 24% overall (14% appropriate
and 9% inappropriate). At 1 year, the probabilities of an
appropriate shock (6.1%) and an inappropriate shock (5.0%)
were not signiﬁcantly different (P=0.06). The only notable
difference in cumulative probability of ﬁrst device therapy
across CMS CED characteristics, in unadjusted analysis, was
that patients with NIDCM <9 months’ duration were more
likely to receive an inappropriate therapy (18%) compared with
patients with NIDCM >9 months’ duration (13%), NIDCM of
unknown duration (12%), and ischemic cause (11%, P=0.05;
Figure 3). The cumulative probability of ﬁrst appropriate
therapy did not differ by ischemic versus nonischemic causes
nor other CMS CED characteristics.
Device Therapy Predictors
In multivariable modeling, men were nearly twice as likely as
women to receive an appropriate therapy (adjusted hazard
ratio [HR], 1.84; 95% conﬁdence interval [CI], 1.43–2.35), as
were patients with a history of nonsustained VT (HR, 1.73;
95% CI, 1.37–2.20; Table 2). The rate of appropriate therapy
was lower among those of Hispanic ethnicity (HR, 0.68; 95%
CI, 0.49–0.94) compared with non-Hispanic whites. Adjusted
rates of appropriate therapy were not signiﬁcantly different
among the CMS CED patient subgroups compared with their
respective referents.
Patients with atrial ﬁbrillation were more than twice as
likely to receive inappropriate therapies (HR, 2.20; 95% CI,
1.68–2.87). The rate of inappropriate therapy was lower for
patients ≥65 years old compared with younger patients (HR,
0.72; 95% CI, 0.54–0.95) and for those receiving an ICD in
2009 compared with 2006 (HR, 0.66; 95% CI, 0.46–0.95).
Compared with patients receiving single-chamber devices, the
adjusted rate of inappropriate therapy was lower for patients
receiving CRT-D (HR, 0.55; 95% CI, 0.36–0.84). Otherwise,
adjusted rates of inappropriate therapy were similar for CMS
CED subgroups and their referents, including for patients with
NIDCM <9 months’ duration compared with longer NIDCM
durations or ischemic causes.
Sensitivity Analysis Outcomes
In our ﬁrst sensitivity analysis, we determined that the
estimated cumulative probability of appropriate therapies at
3 years could have been 2 to 6 percentage points higher (ie,
Primary Prevenon First Implants
2006-2009
(n=2669)
Final Therapy Cohort
(n=2540, 95.2%)
One or More Device-
Delivered Therapies
(n=738, 29.1%)
Device-Delivered Therapies
(n=2455)
Mean 3.3, Median 2
Appropriate
ATP Alone
(N=778, 32%)
Appropriate 
Requiring Shock
(N=558, 23%)
Inappropriate 
ATP Alone
(N=358, 15%)
Inappropriate 
Requiring Shock
(N=377, 15%)
Unclassiﬁed 
Appropriateness 
ATP Alone
(N=222, 9%)
Unclassiﬁed 
Appropriateness 
Requiring Shock
(N=134, 5%)
Uknown Type
(N=28, 1%)
No Device-Delivered 
Therapies
(n=1802)
Exclusions:
Prior ICD Implant, n=2
No follow-up in health system, n=58
Ejecon Fracon% ≥ 36%, n=69
SUBJECTS
THERAPIES
Figure 1. Application of exclusion criteria to reach ﬁnal study cohort (n=2540 total subjects), with display
of the distribution of type and appropriateness of device-delivered therapies (n=2455 therapies) among the
738 subjects (29%) who received any device-delivered therapy. ATP indicates antitachycardia pacing; and
ICD, implantable cardioverter-deﬁbrillator.
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Table 1. Baseline Characteristics and Incidence (Rate per 100 Person-Years) of Device-Delivered Therapies (Any Type, Any
Appropriateness)
Characteristics
No. of Subjects
(N=2540) %* Mean (SD)
Person-
Years
All Device Therapies
No. of
Therapies
(N=2455)
Incidence
Per 100
Person-Years 95% CI
Sex
Female 653 25.7 1435 464 32.3 29.5–35.4
Male 1887 74.3 4050 1991 49.2 47.1–51.4
Age at implant, y 66.7 (11.5)
≥65 1646 64.8 3629 1493 41.1 39.1–43.3
<65 894 35.2 1855 962 51.9 48.7–55.2
Race/ethnicity
White 1510 59.4 3346 1483 44.3 42.1–46.6
Black 431 17.0 866 526 60.8 55.8–66.2
Hispanic 317 12.5 667 225 33.7 29.6–38.4
Other 282 11.1 605 221 36.5 32.0–41.7
Year of implant
2006 630 24.8 1509 672 44.5 41.3–48.0
2007 588 23.1 1368 662 48.4 44.9–52.2
2008 583 23.0 1399 521 37.2 34.2–40.6
2009 739 29.1 1209 600 49.6 45.8–53.8
Ejection fraction, %
≤30 2182 85.9 4701 2096 44.6 42.7–46.5
31–35 358 14.1 783 359 45.8 41.3–50.8
New York Heart Association class
I 279 11.0 638 273 42.8 38.0–48.2
II 1200 47.2 2664 1233 46.3 43.8–48.9
III 1004 39.5 2087 912 43.7 41.0–46.6
IV 52 2.0 87 37 42.4 30.7–58.5
Device type
Single chamber 905 35.6 1955 869 44.4 41.6–47.5
Dual chamber 811 31.9 1717 888 51.7 48.4–55.2
Biventricular 824 32.4 1812 698 38.5 35.8–41.5
Left ventricular systolic dysfunction cause
Ischemic 1593 62.7 3414 1500 43.9 41.8–46.2
NIDCM,
within 9 mo
183 7.2 410 177 43.2 37.3–50.1
NIDCM, >9 mo 737 29.0 1600 762 47.6 44.4–51.1
NIDCM, timing
not known
27 1.1 61 16 26.2 16.0–42.7
Congestive heart failure
No 94 3.7 232 100 43.1 35.5–52.5
Yes 2446 96.3 5253 2355 44.8 43.1–46.7
Continued
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Table 1. Continued
Characteristics
No. of Subjects
(N=2540) %* Mean (SD)
Person-
Years
All Device Therapies
No. of
Therapies
(N=2455)
Incidence
Per 100
Person-Years 95% CI
Previous coronary artery bypass graft
No 1754 69.1 3781 1751 46.3 44.2–48.5
Yes 784 30.9 1700 704 41.4 38.5–44.6
Previous percutaneous coronary intervention
No 1767 69.6 3819 1811 47.4 45.3–49.7
Yes 772 30.4 1663 644 38.7 35.9–41.8
Chronic lung disease
No 2044 80.5 4458 1938 43.5 41.6–45.5
Yes 495 19.5 1023 516 50.4 46.3–55.0
Diabetes mellitus
No 1480 58.3 3279 1456 44.4 42.2–46.7
Yes 1058 41.7 2199 998 45.4 42.7–48.4
Hypertension
No 678 26.7 1515 623 41.1 38.0–44.5
Yes 1858 73.1 3960 1829 46.2 44.1–48.4
Atrial fibrillation/atrial flutter
No 1741 68.5 3797 1404 37.0 35.1–39.0
Yes 794 31.3 1674 1040 62.1 58.5–66.0
QRS duration/morphological features
<120 ms 1036 40.8 2252 1248 55.4 52.4–58.6
≥120 ms without
LBBB
621 24.4 1300 582 44.8 41.3–48.6
≥120 ms with
LBBB
654 25.7 1499 524 35.0 32.1–38.1
Not fully documented 229 9.0 433 101 23.3 19.2–28.3
Nonsustained ventricular tachycardia
No 2191 86.3 4789 1884 39.3 37.6–41.2
Yes 345 13.6 684 561 82.0 75.5–89.1
Blood urea nitrogen level, mg/dL 24.9 (13.7)
≥26 870 34.3 1732 788 45.5 42.4–48.8
18–25 865 34.1 1944 765 39.3 36.7–42.2
1–17 801 31.5 1796 897 49.9 46.8–53.3
Creatinine level, mg/dL 1.4 (0.9)
≥1.4 865 34.1 1719 795 46.3 43.2–49.6
1.1–1.3 799 31.5 1781 800 44.9 41.9–48.2
0–1.0 871 34.3 1971 855 43.4 40.6–46.4
ACE inhibitor or ARB
No 357 14.1 714 382 53.5 48.4–59.2
Yes 2176 85.7 4763 2071 43.5 41.7–45.4
Continued
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26%–30% rather than 24%) if the appropriateness of all
therapies in the cohort had been classiﬁable. Similarly, for
inappropriate shocks, the cumulative probability could have
been as high as 13% rather than the 9% estimated from the
classiﬁed therapies. However, the simulation results also
show that the correction size was consistent across levels of
study covariates, indicating that the observed measures
of association were stable despite inability to classify some of
the therapies.
In the second sensitivity analysis, among the subset with
partial device setting data available, the proportion with a VT
rate threshold of >200 bpm at implant increased from 6% in
2006 to 18% in 2009. Similarly, the proportion of subjects
with arrhythmia detection enhancement programmed to “on”
at baseline increased over the study accrual period from 2% to
30%. In adjusted analyses, patients with a VT rate threshold of
>200 bpm had a signiﬁcantly lower rate of inappropriate
therapy (HR, 0.51; 95% CI, 0.26–1.00) compared with patients
with a baseline VT rate threshold of <180 bpm, whereas the
rate of appropriate therapy was statistically similar between
the groups (HR, 0.67; 95% CI, 0.39–1.14; Table 3). Although
baseline arrhythmia detection enhancement programmed to
on was associated with a small increased rate of appropriate
therapies (of any type) (HR, 1.50; 95% CI, 1.06–2.14), further
exploration by therapy type shows that this was not the case
for device shocks. The rate of appropriate shocks was lower
among those with baseline arrhythmia detection enhance-
ment programming compared with those without (HR, 0.72;
95% CI, 0.53–1.00; P=0.047). Notably, adjustment for device
settings did not change the observed associations of other
signiﬁcant covariate predictors of appropriate or inappropriate
therapies (Table 3).
Discussion
In this community-based cohort of patients with left
ventricular systolic dysfunction who received an ICD for
primary prevention, nearly one third received at least 1
device therapy over a median follow-up of almost 2.5 years.
Rates of therapy varied by age, sex, and race/ethnicity and
across cardiovascular characteristics; rates of inappropriate
therapies declined for implants after 2006. Notably, device
therapy rates did not signiﬁcantly differ for subgroups of
interest to CMS in their 2005 coverage expansion12 and
were consistent after accounting for differences in device
programming. Results from this “real-world” population help
address evidence gaps for primary prevention ICD use
outside of clinical trials.8,20
Table 1. Continued
Characteristics
No. of Subjects
(N=2540) %* Mean (SD)
Person-
Years
All Device Therapies
No. of
Therapies
(N=2455)
Incidence
Per 100
Person-Years 95% CI
Aspirin
No 828 32.6 1784 829 46.5 43.4–49.8
Yes 1704 67.1 3688 1624 44.0 42.0–46.2
b Blocker
No 211 8.3 469 246 52.5 46.3–59.5
Yes 2322 91.4 5005 2207 44.1 42.3–46.0
Coumadin
No 1724 67.9 3766 1516 40.3 38.3–42.3
Yes 807 31.8 1706 937 54.9 51.5–58.6
Digoxin
No 1776 69.9 3822 1603 41.9 39.9–44.1
Yes 755 29.7 1649 850 51.5 48.2–55.1
Statin
No 574 22.6 1238 699 56.5 52.5–60.8
Yes 1959 77.1 4236 1754 41.4 39.5–43.4
ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CI, conﬁdence interval; LBBB, left bundle branch block; and NIDCM, nonischemic dilated
cardiomyopathy.
*Percentages may not sum to 100% because of rounding/missing values.
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Device Therapy Rates
Rates of device-delivered therapy in this cohort were lower
than reported among participants in the randomized clinical
trials that established efﬁcacy of ICDs for primary
prevention.5,21,22 For example, the 3-year cumulative therapy
rate was lower than reported in MADIT (Multicenter Automatic
Deﬁbrillator Implantation Trial) II, for both appropriate
0 1 2 3
No. at risk [esmated cumulave rate (%)]
Any type 2540
(A)
(B)
(C)
1744 [19.7] 1397 [28.4] 626 [35.6]
Shock-containing 2540 1898 [11.9] 1562 [18.9] 910 [24.0]
0 1 2 3
No. at risk [esmated cumulave rate (%)]
Any type 2540 1843 [11.7] 1498 [18.2] 686 [23.5]
Shock-containing 2540 1976 [  6.1] 1649 [11.0] 983 [14.0]
0 1 2 3
No. at risk [esmated cumulave rate (%)]
Any type 2540 1932 [  7.0] 1635 [  9.5] 951 [12.2]
Shock-containing 2540 1990 [  5.0] 1703 [  6.8] 1005 [  8.9]
Figure 2. Unadjusted Kaplan-Meier estimates for occurrence of ﬁrst device-
delivered therapy, by therapy type, with estimated cumulative probability of
ﬁrst therapy (percentage) at 1, 2, and 3 years for therapy of any appropri-
ateness (A), appropriate therapy (B), and inappropriate therapy (C).
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therapies (34% versus 24%)21 and inappropriate therapies
(18% versus 12%).22 Several factors may explain this. First,
demographic and clinical proﬁles of this community cohort
differ from trial participants.13 Second, rates of evidence-
based medical therapies in this cohort were higher than those
reported in trials.13
Third, with nearly a decade between the conduct of
landmark efﬁcacy trials and our study period, improvements
in device technologies and reﬁned programming strategies
likely contributed to lower risks of therapy in our observa-
tional cohort. Programming strategies, including higher VT
rate thresholds, longer detection delays, advanced detection
A B
0 1 2 3 0 1 2 3
No. at risk [esmated cumulave rate (%)] No. at risk [esmated cumulave rate (%)]
Ischemic 1593 1147 [11.4] 918 [18.0] 431 [23.3] Ischemic 1593 1207 [  6.1] 1004 [  8.4] 612 [11.2]
NIDCM, within 9 mos 183 141 [10.6] 124 [17.1] 55 [25.7] NIDCM, within 9 mos 183 144 [  9.8] 66 [16.8] 59 [18.2]
NIDCM, gt 9 mos 737 533 [12.9] 441 [19.3] 259 [23.7] NIDCM, gt 9 mos 737 563 [  8.3] 484 [10.4] 280 [12.8]
NIDCM, ming unknown 27 27 [  0.0] 21 [12.2] 11 [19.5] NIDCM, ming unknown 27 25 [  3.9] 22 [11.9] 22 [11.9]
C D
0 1 2 3 0 1 2 3
No. at risk [esmated cumulave rate (%)] No. at risk [esmated cumulave rate (%)]
NYHA I 279 213 [10.5] 181 [18.3] 116 [22.9] NYHA I 279 224 [  6.2] 203 [  8.4] 122 [10.5]
NYHA II 1205 896 [11.6] 744 [17.9] 422 [23.1] NYHA II 1205 942 [  7.1] 813 [  9.2] 455 [12.3]
NYHA III 1004 708 [11.8] 557 [18.4] 262 [24.1] NYHA III 1004 743 [  6.9] 608 [10.1] 371 [12.4]
NYHA IV 52 28 [16.8] 20 [23.9] 14 [29.0] NYHA IV 52 34 [11.5] 34 [11.5] 15 [17.0]
E F
0 1 2 3 0 1 2 3
No. at risk [esmated cumulave rate (%)] No. at risk [esmated cumulave rate (%)]
EF% ≤ 30 2182 1570 [11.6] 1272 [18.2] 591 [23.6] EF% ≤ 30 2182 1647 [  7.2] 1393 [  9.6] 828 [11.9]
EF% 31-35 358 273 [12.3] 226 [18.4] 129 [23.4] EF% 31-35 358 290 [  5.8] 242 [  9.0] 133 [13.9]
log-rank p-value
0.81
log-rank p-value
0.050
log-rank p-value
0.75
log-rank p-value
0.67
log-rank p-value
0.87
log-rank p-value
0.87
Figure 3. Unadjusted Kaplan-Meier estimates for occurrence of ﬁrst device-delivered therapy, by baseline clinical strata and therapy
appropriateness, with estimated cumulative probability of ﬁrst therapy (percentage) at 1, 2, and 3 years for left ventricular systolic dysfunction
(LVSD) cause (appropriate therapy; A), LVSD cause (inappropriate therapy; B), New York Heart Association (NYHA) class (appropriate therapy; C),
NYHA class (inappropriate therapy; D), ejection fraction (EF; appropriate therapy; E), and ejection fraction (inappropriate therapy; F). NIDCM
indicates nonischemic dilated cardiomyopathy.
DOI: 10.1161/JAHA.117.008292 Journal of the American Heart Association 9
Device Therapies From Primary Prevention ICDs Greenlee et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on June 4, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
algorithms, and optimized discriminators, have been shown to
reduce the risk of both inappropriate device therapies and the
risk of appropriate (but unnecessary) device therapies (those
that would have terminated spontaneously).23 Although our
study period preceded the publication of MADIT-RIT (Reduce
Inappropriate Therapy), DECREASE (Reduction of Inappropri-
ate ICD Therapies in Patients with Approved Indication for
Primary Prevention of Sudden Cardiac Death), ADVANCE
(Avoid Delivering Therapies for Nonsustained Arrhythmias in
ICD Patients) III, PROVIDE (Programming Implantable Cardi-
overter Deﬁbrillators in Patients with Primary Prevention
Indication to Prolong Time to First Shock), and other recent
studies, with results supportive of such programming
strategies,23–27 it coincides with the reporting of earlier trials,
including EMPIRIC (Comparison of Empiric to Physician-
Tailored Programming of Implantable Cardioverter-
Deﬁbrillators) and PREPARE (Primary Prevention Parameters
Evaluation),28,29 which demonstrated the promise of strategic
or standardized device programming. Given the changes we
observed in baseline device programming over time, it
appears that some strategy reﬁnement was occurring natu-
rally in community practice during the time of our study. Thus,
compared with the original efﬁcacy trial subjects, we believe
the lower rates of therapy observed in this more contempo-
rary and diverse cohort of patients are relevant in providing
more accurate prognostic information for patients undergoing
primary prevention ICD implantation.
Directly comparing device therapy rates across published
observational cohort studies is challenging because of variable
Table 2. Associations of Baseline Characteristics With Time
to First Appropriate and Time to First Inappropriate Device-
Delivered Therapy
Characteristics
Appropriate
Therapy* Inappropriate Therapy*
HR 95% CI HR 95% CI
Sex (male vs female)
1.84 1.43–2.35 1.30 0.94–1.80
Age at implant (≥65 vs <65), y
0.89 0.72–1.11 0.72 0.54–0.95
Race/ethnicity (referent, white)
Black 1.24 0.94–1.63 NA
Hispanic 0.68 0.49–0.94 NA
Other 0.88 0.64–1.20 NA
Year of implant (referent, 2006)
2007 NA 0.75 0.53–1.07
2008 NA 0.76 0.53–1.10
2009 NA 0.66 0.46–0.95
Ejection fraction (31–35 vs ≤30), %
0.98 0.75–1.27 1.00 0.70–1.44
New York Heart Association class (referent, I)
II 1.25 0.91–1.70 1.22 0.73–2.04
III 1.32 0.93–1.88 1.65 0.95–2.84
IV 1.59 0.79–3.19 2.14 0.82–5.59
Device type (referent, single chamber)
Dual chamber 0.97 0.75–1.25 1.04 0.75–1.44
Biventricular 0.96 0.70–1.32 0.55 0.36–0.84
Left ventricular systolic dysfunction cause (referent, ischemic)
NIDCM, within 9 mo 1.02 0.70–1.48 1.38 0.88–2.18
NIDCM, >9 mo 1.16 0.91–1.48 1.12 0.79–1.59
NIDCM, timing not known 0.80 0.29–2.18 1.06 0.33–3.44
Congestive heart failure (yes vs no)
NA 1.33 0.52–3.37
Previous coronary artery bypass graft (yes vs no)
NA 0.82 0.58–1.15
Previous percutaneous coronary intervention (yes vs no)
0.74 0.59–0.93 NA
Diabetes mellitus (yes vs no)
1.20 0.99–1.45 NA
Atrial fibrillation/atrial flutter (yes vs no)
1.12 0.92–1.37 2.20 1.68–2.87
QRS duration/morphological feature (referent, <120 ms)
≥120 ms without LBBB 0.87 0.68–1.12 0.71 0.37–1.38
≥120 ms with LBBB 0.79 0.60–1.05 0.61 0.42–0.90
Not fully documented 0.46 0.24–0.87 1.01 0.70–1.46
Continued
Table 2. Continued
Characteristics
Appropriate
Therapy* Inappropriate Therapy*
HR 95% CI HR 95% CI
Nonsustained ventricular tachycardia (yes vs no)
1.73 1.37–2.20 1.27 0.90–1.80
Blood urea nitrogen level, (referent, ≥26), mg/dL
18–25 0.85 0.68–1.07 1.29 0.93–1.79
1–17 1.12 0.89–1.42 1.46 1.04–2.04
ACE inhibitor or ARB (yes vs no)
NA 0.78 0.56–1.11
Digoxin (yes vs no)
1.17 0.96–1.43 NA
Statin (yes vs no)
NA 0.83 0.61–1.13
ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CI,
conﬁdence interval; HR, hazard ratio; LBBB, left bundle branch block; NA, not applicable
to that model because variable was dropped at the screening stage; and NIDCM,
nonischemic dilated cardiomyopathy.
*Models control for study site as a random effect.
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populations, differential follow-up time, and, in some cases,
restriction of outcomes to shocks alone. Nevertheless, therapy
rates in our cohort are comparable to those reported in recent
observational studies in Canada, Europe, and the United
States.30–33 In the OMNI (Assessing Therapies in Medtronic
Pacemaker, Deﬁbrillator, and Cardiac Resynchronization Ther-
apy Devices) study, for example, 25% received an appropriate
therapy over a mean of 39 months compared with 20% over
27 months in the LS-ICD.33 Advantages of the observations
from the LS-ICD include the large diverse study population and
rigorous clinical adjudication process.
Device Therapy Predictors
Higher rates of appropriate ICD therapies were observed in
men and in non-Hispanic whites compared with Hispanic
patients, whereas higher rates of inappropriate therapies were
noted in younger patients. Higher rates of therapy in men
have been reported from clinical trials34 and other observa-
tional studies.30,32,35,36 The mechanisms for this are unclear,
but men may be more likely to develop malignant ventricular
arrhythmias compared with women, which may also explain
greater ICD efﬁcacy observed in men in some studies.37 The
relation between younger age and inappropriate therapies has
been reported in some,38,39 but not in other,22 studies, and
may result from more robust atrioventricular conduction of
supraventricular arrhythmias among younger patients. The
considerably lower risk of appropriate therapy among His-
panic patients is novel and warrants further investigation,
Table 3. Associations of Selected Baseline Characteristics
With Time to First Appropriate and Time to First Inappropriate
Device-Delivered Therapy, Sensitivity Analysis in Subset With
Baseline Device Settings (N=1889)
Variable
Final Model Rerun
in Device Settings
Subset
Final Model, Including
Device Setting
Variables in Device
Settings Subset
HR 95% CI HR 95% CI
Appropriate therapy*
Sex (male vs female)
1.81 1.34–2.45 1.83 1.35–2.47
Race/ethnicity (referent, white)
Black 1.27 0.92–1.76 1.29 0.93–1.78
Hispanic 0.78 0.54–1.13 0.78 0.54–1.14
Other 1.07 0.73–1.57 1.08 0.73–1.58
Previous percutaneous coronary intervention (yes vs no)
0.71 0.53–0.96 0.72 0.53–0.98
Nonsustained ventricular tachycardia (yes vs no)
2.03 1.52–2.71 2.04 1.53–2.73
Ventricular tachycardia rate threshold setting, (referent, <180), beats per
minute
180–199 NA NA 0.74 0.54–1.01
≥200 NA NA 0.67 0.39–1.14
Enhanced detection setting (yes vs no)
NA NA 1.50 1.06–2.14
Inappropriate therapy†
Age at implant (≥65 vs <65), y
0.62 0.44–0.88 0.60 0.43–0.85
Year of implant (referent, 2006)
2007 0.71 0.45–1.13 0.74 0.46–1.17
2008 0.64 0.40–1.02 0.65 0.40–1.06
2009 0.68 0.44–1.07 0.66 0.40–1.06
Device type (referent, single chamber)
Dual chamber 1.46 1.00–2.13 1.29 0.87–1.92
Biventricular 0.60 0.35–1.03 0.55 0.32–0.94
Atrial fibrillation (yes vs no)
2.29 1.65–3.18 2.25 1.62–3.13
QRS duration/morphological features (referent, <120 ms)
≥120 ms without LBBB 0.74 0.47–1.15 0.75 0.48–1.17
≥120 ms with LBBB 0.97 0.61–1.54 0.99 0.62–1.57
Not fully documented 0.93 0.48–1.82 1.26 0.59–2.72
Blood urea nitrogen level (referent, ≥26), mg/dL
18–25 1.10 0.73–1.45 1.09 0.72–1.64
1–17 1.40 0.94–2.09 1.37 0.92–2.04
Continued
Table 3. Continued
Variable
Final Model Rerun
in Device Settings
Subset
Final Model, Including
Device Setting
Variables in Device
Settings Subset
HR 95% CI HR 95% CI
Ventricular tachycardia rate threshold setting (referent, <180),
beats per minute
180–199 NA NA 0.75 0.50–1.11
≥200 NA NA 0.51 0.26–1.00
Enhanced detection setting (yes vs no)
NA NA 1.17 0.69–2.00
CI indicates conﬁdence interval; HR, hazard ratio; LBBB, left bundle branch block; and
NA, not applicable to that model.
*In addition to variables shown, ﬁnal model covariates also included age at implant,
ejection fraction, New York Heart Association class, device type, left ventricular systolic
dysfunction cause, diabetes mellitus, atrial ﬁbrillation, QRS duration/morphological
features, blood urea nitrogen level, digoxin, plus study site as a random effect.
†In addition to variables shown, ﬁnal model covariates also included sex, ejection
fraction, New York Heart Association class, left ventricular systolic dysfunction cause,
congestive heart failure, previous coronary artery bypass graft, nonsustained ventricular
tachycardia, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker,
statins, plus study site as a random effect.
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especially given reports of similar survival associated with ICD
therapy in Hispanic and non-Hispanic white patients.40
Patients with a history of nonsustained VT were at
increased risk for appropriate device therapies, consistent
with prior reports that this rhythm is a risk marker in patients
with structural heart disease.41 Atrial ﬁbrillation, a risk factor
for inappropriate therapies in previous studies,22,38,39 was
associated with a >2-fold higher risk for inappropriate therapy
during follow-up. An understanding of the magnitude of this
risk, as well as the impact of evidence-based therapies (eg, AV
nodal blockers) on this risk, will be informative to patients
with atrial ﬁbrillation considering ICD therapy.
CMS Coverage With Evidence Development
Subgroups
Device therapies among the subgroups deﬁned in the CMS
CED decision have not been well characterized despite
importance to policy and clinical decision makers.12 A key
ﬁnding of our study is that therapy rates were not signiﬁcantly
different for patients within these subgroups compared with
the broader population of patients receiving ICDs, with the
exception of those receiving CRT-D, who had signiﬁcantly
lower risk of inappropriate therapy compared with those
receiving single-chamber devices. An interesting result in
unadjusted analysis, that the cumulative incidence of inap-
propriate therapy was somewhat higher for patients with
NIDCM <9 months’ duration compared with longer durations
of NIDCM or ischemic causes, was not borne out in adjusted
results. Our ﬁndings among these key CMS CED subgroups
are consistent with results from the OMNI study,33 which
addressed similar questions but was limited to remote
monitoring patients, a single device manufacturer, and a
much higher proportion of CRT-D devices.
We recognize that the occurrence of an appropriate device
therapy is not equivalent to the provision of device beneﬁt (ie,
a device therapy that prevents an arrhythmic death that would
have otherwise resulted if the therapy were not delivered).
Some malignant ventricular arrhythmias that prompt delivery
of an appropriate therapy may have otherwise terminated
spontaneously, rendering an appropriate therapy as unneces-
sary. However, we also know that the 2 concepts are
correlated, and the results can help distinguish characteristics
of those who may be beneﬁtting, those who receive
inappropriate therapies that are deﬁnitely not providing
beneﬁt, and those who are not receiving therapies at all.
Limitations
Certain factors should be considered in interpreting the
results of this study. A rigorous process for central
adjudication of therapy events is a particular strength of
this study. All therapy events were reviewed independently
by at least 2 members of the clinical review panel, with any
discrepancies resolved through consensus discussion. Cases
selected at random for quality assurance review by an
external panel of electrophysiology experts showed high
agreement on therapy appropriateness from the central
reviewers and the external panel (Κ=0.87). Despite this,
some therapy events could not be designated as appropriate
or inappropriate because of insufﬁcient or inconclusive
records. However, in sensitivity analyses, the potential
impact of this appeared to be modest and primarily limited
to the magnitude of observed therapy rates and not to the
association of therapy predictors. Second, in this observa-
tional study, we cannot fully exclude the possibility of
residual confounding despite inclusion of a wide range of
measured characteristics.
Finally, information on device settings was not available for
all patients, and longitudinal changes in device programming
for individual patients were not considered. However, in a
sizable subset of subjects, we did observe secular trends in
baseline settings over the accrual period of our study.
Furthermore, the associations of baseline device settings with
therapy delivery in this observational cohort are compatible
with results of trials assessing the impact of device program-
ming strategies. These include a reduction in the rate of
inappropriate therapies with a VT rate threshold >200 bpm in
a sensitivity analysis and less appropriate shocks with
arrhythmia detection enhancement set to on, possibly
reﬂecting reduction of “appropriate but unnecessary” shocks
(ie, those delivered for VT that would otherwise have resolved
spontaneously). Furthermore, adjusting for baseline device
settings did not substantially alter the results or conclusions
on the associations of other potential predictor covariates in
our primary analysis. This suggests that factors other than
device programming are responsible for observed relation-
ships and that, consequently, our results provide relevant
insights for current clinical practice. To our knowledge, the
LS-ICD is the only observational study of the rates and general
predictors of all device therapies that has ascertained device
programming data and explored their relation to the study
outcomes.
Conclusion
The LS-ICD provides estimates of the incidence and correlates
of appropriate and inappropriate device therapies in adults
receiving primary prevention ICDs in contemporary clinical
practice. Rates of therapies in this cohort were lower than
reported from clinical trials and varied by certain patient and
device characteristics, providing clinicians and patients with
useful prognostic data for the growing population of patients
treated with ICDs for the primary prevention of sudden
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cardiac death. Inappropriate therapies were less common in
more recent implants, which is compatible with recognized
improvements over time in device programming. The results
also offer policy stakeholders conﬁdence in the coverage
expansion decisions originally made on the basis of the select
populations of randomized clinical trials.
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